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ABSTRACT  
Background and objective: Multidrug-resistant Acinetobacter baumannii has one of the most serious nosocomially acquired gram 
negative infection in Intensive Care Unit (ICU). The gradual increase in incidence of this pathogen reflects their de-novo selection due to 
antibiotic usages and its ability to spread between patients. This study was undertaken to detect resistance to carbapenems in clinical 
isolates of A.baumannii in our ICU set up and to assess the rate of carbapenemase and MBL production among the isolates with the 
therapeutic options available against them. Material and methods: A.baumannii was identified by conventional methodology and 
susceptibility profile was determined by disc diffusion method. Carbapenem resistant isolates were further checked for mettalo beta 
lactamases (MBL) assay by EDTA disc synergy test and Minimum inhibitory concentration determination by agar dilution method. 
Results: 71.87% (n=46) of isolates showed resistance to Imipenem by disc diffusion method. 82.6% (n=38) of isolates were MBL producer 
both by phenotypic EDTA disc synergy test and MIC determination test by agar dilution method. The susceptibility profiles of 
A.baumannii strains towards colistin, polymyxinB and tigecycline were 90.62%, 57.81% and 78.12% respectively. Conclusion: Detection 
as well as awareness of this MBL producing A.baumannii in a hospital set up, coupled with judicious antimicrobial therapy based on 
sensitivity profiles will help us fight against this deadly menace. 
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INTRODUCTION 
Acinetobacter baumanii is a ubiquitous pathogen, which has 
recently emerged as an important causative agent of hospital 
acquired infection (HAI). It has greater propensity to acquire 
resistance determinants leading to multidrug resistance (MDR), 
hence causing therapeutic problems and hospital outbreaks. 
[1,2] To compounds this problem, A.baumannii resistant to all 
antimicrobial agents have also been reported.[3] So MDR 
Acinetobacter is a burning issue in the current antibiotic era.[4] 
 Carbapenems are widely used to treat MDR nosocomial 
infections in mechanically ventilated patients and intravenous 
devices infections. Mortality rate of these infections ranges from 
19-54%.[5] Resistance to carbapenems are now increasing 
unfortunately. The main mechanism being production of 
carbapenemase, other non-enzymatic mechanisms are change in 
outer membrane protein, multidrug efflux pump and alteration 
in outer membrane binding protein.[6] Acinetobacter baumannii 
is responsible for approximately 2-10% of all gram negative 
infection in intensive care units (ICUs).[7] Emergence of metallo-
β-lactamase (MBL) producing A. baumannii is a matter of 
concern in ICU.[8]  MDR Acinetobacter baumanii is defined as 
those isolates resistant to at least three classes of antimicrobial 
agents penicillins or cephalosporins with beta-lactamase 
inhibitor combination, fluroquinolones and aminoglycosides. 
Extreme-drug-resistant (XDR) are defined as isolates that are 
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resistant to above mentioned antibiotics plus resistant to 
carbapenem.[9] 
MATERIALS AND METHODS 
Research study design  
The prospective study was done from March 2014 to December 
2014. Necessary ethical approval was taken. The study was 
carried out in the department of Medical Microbiology. Clinical 
samples were collected from our tertiary care set up. Inclusion 
criteria: Patients were eligible for participation in the study if 
they had signs and symptoms of nosocomial surgical site 
infection, nosocomial urinary tract infection, infected 
tracheostomy or bacteremia. Full history was obtained from all 
patients including: a) duration of hospitalization, b) presence of 
associated risk factors as: diabetes mellitus, previous antibiotic 
therapy shortly before the occurrence of infection, c) presence 
of medical devices such as urinary catheters, mechanical 
ventilation or peripheral intravenous catheters. Exclusion 
criteria:  All those persons with disease manifestations during 
admission or developed within 48 hours of admission were 
excluded.  
Sample size: A total of 2200 samples were examined from 
different age groups admitted in ICU.  
Methodology: Specimen such as blood, endotracheal aspirate, 
urine, pus and wound swabs were sent to the microbiology 
laboratory and were processed as per standard methods. Blood 
was collected in blood culture bottles containing brain heart 
infusion broth. Subcultures were done on blood agar and 
MacConkey agar and incubated aerobically at 370C for 24 hours. 
Isolates were identified as Acinetobacter baumannii by a battery 
of tests like morphology, motility, oxidase, catalase, indole, 
urease, nitrate, citrate tests and oxidation-fermentation reactions 
of glucose, lactose, xylose, maltose, mannitol (Hugh Leifson 
method), lysine, arginine decarboxylase test and gelatin 
lequifaction test.[7] Antibiotics tested for non-fermenter by disc 
diffusion method were piperacillin (100µg), piperacillin/ 
tazobactum (100µg/10µg), ceftazidime (30µg), cefepime 
(30µg), ceftriaxone (30µg),tigecycline (15µg), polymyxin B 
(300units), colistin (10µg)), amikacin (30µg), ciprofloxacin 
(5µg), imipenem (10µg)   [Hi Media laboratories  Mumbai, 
India], MBL production was detected in imipenem resistant 
isolates by imipenem-EDTA combined disc method.[11] Zone 
diameter of >7mm with imipenem (10ug)+ EDTA (750ug) 
combination disc when compared to only imipenem disc (10ug) 
is considered carbapenem producer. Also modified Hodge test 
(MHT) was performed as per CLSI guideline for detection of 
carbapenemase. Also these patients were clinically reviewed for 
risk factor assessment and followed till discharge. 
RESULTS 
During the period of study from March 2014 to December 2014 
a total of 1589 samples were examined from different age 
groups admitted in ICU. Out of total 536 isolates non-
fermentors account for 40.29% (216) in this study period. 
Pseudomonas was the most common nonfermenter (140, 
64.81%) followed by Acinetobacter baumannii (64, 29.62%). 
Table 1 shows the numbers of A. baumannii isolated from 
different clinical samples.  
Table 1. Sources of the A.baumannii isolates 
         Samples Total Percentage % 
 
Endotracheal secretion 23 35.9% 
Urine 21 32.8% 
Blood 10 15.6% 
Pus 10 15.6% 
Total 64 100 
 
The male: female ratio was 1.5:1. Most of these patients had 
clinical history of COPD, bronchial asthma with features of 
respiratory failure. Infection in neonates was common in 
preterm babies. In 81.42% samples growth was monomicrobial. 
In 18.58% samples growth was polymicrobial. E. coli was the 
most common associated pathogen with Acinetobacter in case 
of urinary tract infection whereas Staphylococcus aureus was 
the associated organism in the case of wound infection, cellulitis 
and abscess. Out of 64 isolates, 46 (71.87%) Acinetobacter 
baumannii were resistant to imipenem by disc diffusion test. 
Among the imipenem resistant isolates 38 (82.6%) A. 
baumannii was found to be MBL producer by both imipenem 
EDTA combined disc method and MHT assay. The sensitivity 
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profile of MBL positive A. baumannii was different from that of 
MBL nonproducer, but for only colistin maximum no 58 
(90.62%) of isolates were found to be sensitive (Table-2).   
Table-2 Susceptibility pattern of Acinetobacter baumannii 





Piperacillin 20 (31.25%) 44 (68.75%) 
Piperacillin/tazobactum 23 (35.9%) 41 (64.06%) 
Polymyxin B 37 (57.81%) 27 (42.18%) 
Ceftazidime 15 (23.4%) 49 (76.57%) 
Cefepime 17 (26.56%) 47 (73.37%) 
Ceftriaxone 14 (21.87%) 50 (78.12%) 
Tigecycline 50 (78.12%) 14 (21.87%) 
Colistin 58 (90.62%) 06 (9.37%) 
Ciprofloxacin 21 (32.81%) 43 (67.18%) 
Imipenem 18 (28.12%) 46 (71.87%) 
Amikacin 29 (45.31%) 35 (54.68%) 
piperacillin (100ug), piperacillin/tazobactum (100ug/10ug), 
polymyxin B (50ug), ceftazidime (30ug), cefepime (30ug), 
ceftriaxone (30ug),tigecycline (15ug), polymyxinB (300units), 
colistin (10ug)),  [Hi Media laboratories  Mumbai, India], 
imipenem (10ug). 
Acinetobacter infection was more common in persons aged over 
40 yrs however the difference was not statistically significant 
when compared with the distribution among imipenem sensitive 
A. baumannii infected patients (P= 1). (Table 3).   Out of the risk 
factors assessed that were found to be significantly associated 
with MBL production (p<0.05) like hospital stay for more than 
8 days, indwelling urinary catheter, continuous mechanical 
ventilation for more than 48 hours and prolonged antimicrobial 
therapy within 30 day of positive culture but underlying co 
morbid conditions like diabetes mellitus, other endocrinopathies 
were not significantly associated. The overall mortality in MBL 
positive patients was found to be 21% and incidence of MBL 
was more in male patient. 
Table 3 Risk factors associated with imipenem resistant 
Acinetobacter baumannii infection 












Age >40 24 52.17 10 55.55 P=1  
<40 22 47.82 8 44.44 
External 
device 
Yes 6 13.04 12 66.66 P<0.00
1  




Yes 10 21.73 13 72.22 P=0.00
3  




Yes 11 23.91 11 61.11 P<.008  
No 35 70.08 7 38.88 
Underlying 
disorders 
Yes 22 47.82 11 61.11 P=.410
4  
No 24 52.17 7 38.88 
P<0.05 is significant, P<0.001 is highly significant 
DISCUSSION  
Acinetobacter species has very rapidly emerged as serious MDR 
pathogen causing life threatening infection both in community 
and hospital. [12] It is found in nature, soil, and also in skin as 
commensal. Infection is commonly aerosolly transmitted. 
Potential risk factors for development of MDR Acinetobacter 
nosocomial infections are prior use of broad spectrum 
antibiotics, cross infection by hands of hospital staff, ventilator 
machine. In our study at our ICU set up though overall 
Acinetobacter infection was 11.94%, but respiratory infection 
due to Acinetobacter in mechanically ventilated patients in ICU 
was 37.70% (23 isolates of Acinetobacter out of 64 isolates 
isolated from ET tube suction in mechanically ventilated 
patients). According to one recent study, Acinetobacter spp was 
responsible for 35% of ventilator associated pneumonia making 
it most conspicuous and dominant pathogen among all bacteria 
encountered in that study.[13] This study shows that prevalence 
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rate of MBL producing Acinetobacter spp is 7% when isolated 
from clinical samples in our hospital, which is lower than that 
of other similar studies in Indian subcontinent.[4,5] Imipenem 
resistant strains were multidrug resistant except for colistin 
(90.62% sensitive)  and polymyxin B (57.81% sensitive), hence 
necessitating cautious use of these antibiotics.  
A total of 64 Acinetobacter isolates were collected from patients 
in the ICU of our tertiary care set up. Acinetobacter baumannii 
isolates were obtained from different clinical samples including 
23 (35.9%) endotracheal aspirate, 21(32.8%) urine, 10 (15.6%) 
blood, and 10(15.6%) pus (Graph 1). Using disc diffusion 
method to test susceptibility of Acinetobacter isolates to 
different antimicrobials, according to the Clinical Laboratory 
Standard Institute’s guidelines (CLSI, 2014) we found that; the 
highest sensitivity of A. baumannii was for colistin (90.62%), 
followed by tigecycline (78.12%), and then polymyxin B 
(57.81%). The lowest sensitivity of A.baumannii was 
ceftriaxone (21.87%), followed by ceftazidime, cefepime and 
imipenem (Table2). 40 (62.5%) A.baumannii isolates were 
MDR with resistant to ceftriaxone, piperacillin, amikacin, 
ceftazidime, and ciprofloxacin and 37 (57.81%) were XDR with 
resistant to imipenem in addition. These findings are well 
corroborated with the findings of similar studies. [14,15] 
 
Graph 1. Different types of infections caused by 
Carbapenem resistant A. baumannii 
High level of imipenem resistance was obtained by disc 
diffusion method in 46 (71.87%)   isolates of Acinetobacter   
baumannii. Of these 46 imipenem resistant A.baumannii 38 
isolates (82.6%) metallo-β-lactamase producers (increase of 
≥7mm in zone diameter of EDTA containing imipenem disc 
compared to imipenem disc) which is in accordance with similar 
studies.[16,17] Six isolates were MBL negative.    
There were 64 cases of health care associated infection caused 
by A.baumannii, of these cases there were 46 cases caused by 
imipenem resistant A.baumannii, 12 (26.08%) cases of infected 
tracheostomy, 12 (26..08%) cases of nosocomial urinary tract 
infection, 10 (21.73%) cases of septicemia, 10 (21.73%) cases 
of surgical site infection and 2 (4.34%) case of infected bed sore 
in ICU patient (Graph-1). These findings matches with the 
findings of Manchanda V et al.[13] 
In our study, we found that imipenem resistant A .baumannii 
infection were more common among patients with history of 
prior exposure to broad spectrum antibiotics shortly before the 
occurrence of imipenem resistant A.baumannii infection with a 
highly statisticahis rapid sprelly significant difference compared  
to patient with imipenem sensitive A.baumannii infection 
(p=0.004). We also found that patient who have external devices 
were more liable to develop imipenem resistant A.baumannii 
infections with a statistically significant effect as a risk factor 
(p=0.03). There was also a statistically significant association 
between prolonged hospital stay for 10 days or more and 
infection with imipenem resistant A.baumannii (p=0.002). 
Imipenem resistant A.baumannii infections were more common 
among patients aged over 40 years, however the difference was 
not statistically significant when compared with the distribution 
among imipenem sensitive A.baumannii infected patients. 
(p=0.2) 
Rapid emergence of carbapenem resistant MBLs producing 
A.baumannii in our clinical study is alarming and is due to 
excessive use of that group of antibiotic. Hence, appropriate 
antibiotic therapy after proper antimicrobial susceptibility 
testing and reporting and following strict antibiotic policies and 
hospital infections control measures are mandatory to overcome 
this rapid spread of carbapenem resistant. As monotherapy 
carbapenem is often associated with treatment failure and 
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development of antimicrobial resistance combination therapy 
with any carbapenem with colistin is more feasible approach.  A 
limitation of the current study was lack of genotypic 
confirmation for the presence of carbapenem hydrolyzing genes. 
There is need for genetic analysis of MBLs enzymes. 
Carbapenem resistant A.baumannii is emerging as an important 
pathogen in our ICU. Antibiotic selective pressure is an 
important cause of emergence of MDR A.baumannii infection 
in our health care settings. The high prevalence of antibiotic 
resistance observed in the current study is significant, as only 
few therapeutic options are available for treatment. New 
antibiotics are needed to treat MDR A.baumannii.  
CONCLUSION 
The present study provided valuable information about the 
effect of colistin that can be used in our health care facility. 
Infection control practices and antibiotic resistance surveillance 
should be carried out regularly to decrease the spread and impact 
of A.baumannii. Detection and molecular characterization of 
MBL producing A.baumannii strains is recommended for the 
purposes of infection control and prevention. 
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